Table of Content

Archive

Autumn 2004, Vol. 12 No. 3

H.K. Dermatol. Venereol. Bull. (2004) 12, 133-142


Review Article

Biological breakthroughs in the treatment of psoriasis

SY Cheng 鄭秀儀

Abstract
Psoriasis is recently found to be an immunological disease. This leads to the possibility of developing selectively targeted biological therapeutic agents. These biological agents are designed to block certain points in the pathogenetic pathway and subsequently result in decrease in clinical activity. This review briefly discusses the immunological basis of psoriasis and the underlying mechanisms of four biological agents: efalizumab, alefacept, infliximab and etanercept. Results of updated clinical studies relating the use of these agents in the treatment of moderate to severe psoriasis are also reviewed.